Cancer Today Spotlights Lynx Dx’s MPS2 as a Breakthrough At-Home Prostate Cancer Test

In a recent feature, Cancer Today explores how MyProstateScore 2.0 (MPS2) may help men avoid unnecessary or repeat prostate biopsies by offering a more accurate and less invasive risk assessment.

The article highlights how MPS2 analyzes 18 cancer-specific genes through a simple urine test, allowing men with elevated PSA levels to better understand their risk of clinically significant prostate cancer without immediately resorting to biopsy.

Citing recent clinical findings, Cancer Today highlights that MPS2 can preemptively identify up to 53% of men whose next biopsy would be negative for clinically significant prostate cancer, underscoring its potential to reshape early prostate cancer detection. This impact is further amplified with the test now available for at-home use and covered by Medicare and many private insurers.